Dapagliflozin clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Dapagliflozin Clinical Trials: Efficacy and Safety in Diabetes and Cardiovascular Disease
Dapagliflozin in Type 2 Diabetes: Glycemic Control and Weight Loss
Clinical trials have shown that dapagliflozin, when added to metformin (with or without sulfonylurea), significantly improves glycemic control in patients with type 2 diabetes who are inadequately controlled on these agents. Over 24 weeks, dapagliflozin reduced HbA1c, fasting plasma glucose, body weight, and systolic blood pressure compared to placebo. More patients achieved target HbA1c levels with dapagliflozin, but there was a higher incidence of hypoglycemia and genital infections, while urinary tract infection rates were similar between groups . Long-term studies up to 102 weeks confirmed sustained reductions in HbA1c, fasting plasma glucose, and body weight, with rare and non-severe hypoglycemia. Genital and urinary tract infections were more common with dapagliflozin than placebo .
Dapagliflozin in Type 1 Diabetes: Adjunct to Insulin Therapy
In patients with type 1 diabetes, dapagliflozin as an add-on to adjustable insulin therapy led to significant reductions in HbA1c, insulin dose, and body weight over 24 weeks. The risk of hypoglycemia was similar to placebo, but there was an increased risk of diabetic ketoacidosis (DKA) with dapagliflozin Mathieu2018Dandona2017. These findings suggest dapagliflozin can improve glycemic control in type 1 diabetes, but careful monitoring for DKA is necessary.
Cardiovascular Outcomes: DECLARE–TIMI 58 and Heart Failure Trials
The DECLARE–TIMI 58 trial was a large, randomized, placebo-controlled study designed to assess the cardiovascular safety and efficacy of dapagliflozin in patients with type 2 diabetes and either established atherosclerotic cardiovascular disease or multiple risk factors. The primary outcomes included major adverse cardiovascular events (MACE) and a composite of cardiovascular death or hospitalization for heart failure. This trial aimed to determine if dapagliflozin could reduce the occurrence of major cardiovascular events and was the largest of its kind for SGLT-2 inhibitors .
In patients with heart failure with reduced ejection fraction (HFrEF), dapagliflozin rapidly reduced the risk of cardiovascular death or worsening heart failure, with benefits evident as early as 28 days after starting treatment. Patients with a recent history of heart failure hospitalization experienced the greatest absolute risk reduction . Another trial (DEFINE-HF) found that dapagliflozin increased the proportion of patients with clinically meaningful improvements in heart failure-related health status or natriuretic peptide levels, regardless of diabetes status .
Dapagliflozin in Heart Failure with Preserved Ejection Fraction
The DELIVER trial enrolled patients with heart failure and mildly reduced or preserved ejection fraction (LVEF >40%), with or without type 2 diabetes. This large trial included high-risk, well-treated patients and aimed to evaluate the effects of dapagliflozin on cardiovascular death, heart failure hospitalization, or urgent heart failure visits .
Dapagliflozin in Chronic Kidney Disease
The DAPA-CKD trial was designed to assess the effect of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD), both with and without type 2 diabetes. Participants had a wide range of underlying kidney diseases and were already receiving standard renin–angiotensin system blocking therapy. The trial aimed to determine the efficacy and safety of dapagliflozin in CKD stages 2–4 with increased albuminuria .
Dapagliflozin in Acute Myocardial Infarction
The DAPA-MI trial is investigating dapagliflozin in patients without diabetes who have had a recent myocardial infarction and impaired left ventricular function. The trial uses a composite outcome including death, heart failure hospitalization, nonfatal MI, atrial fibrillation/flutter, new onset diabetes, heart failure symptoms, and weight loss. This innovative registry-based trial design allows efficient recruitment and outcome assessment .
Conclusion
Dapagliflozin has demonstrated significant benefits in glycemic control, weight reduction, and cardiovascular and renal outcomes across a range of patient populations, including those with type 1 and type 2 diabetes, heart failure, and chronic kidney disease. While generally well tolerated, dapagliflozin is associated with increased risks of genital infections and, in type 1 diabetes, diabetic ketoacidosis. Ongoing and future trials continue to expand our understanding of dapagliflozin’s role in cardiovascular and renal protection beyond glycemic control Matthaei2015Mathieu2018Wiviott2018+7 MORE.
Sources and full results
Most relevant research papers on this topic